Discover an intriguing stock idea with Mankind Pharma showing signs of a rebound and potential upside in price action.

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at one-tenth of the original cost.

Mankind Pharma launches affordable empagliflozin in India for diabetes: Our Bureau, Mumbai Thursday, March 13, 2025, 17:30 Hrs [IST] Mankind Pharma has launched its affordable gen ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

Trump had earlier said on March 24 that he will announce tariffs on automobiles, pharmaceuticals and aluminum in the near ...

Mankind Pharma has launched generic versions of diabetes medication Empagliflozin under brand names Empaglyde, Empagreat, and Dynaduo, offering affordable treatment options.

IST, the barometer index, the S&P BSE Sensex, slipped 259.73 points or 0.34% to 77,348.12. The Nifty 50 index declined 66.35 points, or 0.28%, to 23,525.60.

Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheims patent. Mankind ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

Rajeev Juneja, vice chairman and managing director of Mumbai, Indian-based drugmaker Mankind Pharma (NSE: MANKIND), today announced that the company is launching the generic version as well as its ...

Mankind Pharma has launched a generic version of Empagliflozin in India under the brands Empaglyde, Empagreat, and Dynaduo. The launch breaks cost barriers, offering the medication at competitive ...